Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030
ABSTRACT Background Hepatoblastoma (HB) is the most common primary pediatric hepatocellular carcinoma, and the five‐year survival rate for HB is the lowest among childhood cancers, as 20% of cases are chemotherapy resistant or unresectable. Understanding the global burden of HB and future trends in...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.71163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221909101674496 |
|---|---|
| author | Xiaoyu Huang Zhiqiang Zhang Qiong Wu Shaoyang Kang Xinyue Yang Fengmei Wang |
| author_facet | Xiaoyu Huang Zhiqiang Zhang Qiong Wu Shaoyang Kang Xinyue Yang Fengmei Wang |
| author_sort | Xiaoyu Huang |
| collection | DOAJ |
| description | ABSTRACT Background Hepatoblastoma (HB) is the most common primary pediatric hepatocellular carcinoma, and the five‐year survival rate for HB is the lowest among childhood cancers, as 20% of cases are chemotherapy resistant or unresectable. Understanding the global burden of HB and future trends in HB burden is urgently needed for gastroenterology and hepatology specialists and pediatricians. This study aims to provide a comprehensive assessment of the global burden of hepatoblastoma, predict future trends over the next decade, and offer insights into its management. Methods Using data from the Global Burden of Disease 2021, trends in HB‐related mortality and disability‐adjusted life years (DALYs) were analyzed. Age‐standardized rates (ASR) and estimated annual percentage changes (EAPC) were employed to measure trends in these outcomes. Joinpoint regression identified trends, while Bayesian age‐period‐cohort (BAPC) modeling projected the future burden. Results Although the global number of HB‐related deaths decreased from 1990 to 2021, the number of deaths in 2021 in low socio‐demographic index (SDI) regions remained comparable to 1990 levels, with a notable upward trend in 27 countries, particularly in West Africa. Mortality and DALYs rates were highest in the early neonatal period, with the 2–4 years age group also showing the greatest burden. Projections indicate a global decline in HB burden from 2021 to 2030, but regions such as West Africa are likely to face persistent challenges. Conclusions In light of rapid population growth and escalating poverty in Africa, early screening and intervention for hepatoblastoma, particularly among children under five in low SDI regions, are critical to reducing the disease burden. These findings have significant implications for liver health policy, emphasizing the need for targeted interventions based on age and region to mitigate the impact of hepatoblastoma. |
| format | Article |
| id | doaj-art-bac0b7d179854eef914f9ffa0aa95dde |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-bac0b7d179854eef914f9ffa0aa95dde2025-08-26T10:58:44ZengWileyCancer Medicine2045-76342025-08-011416n/an/a10.1002/cam4.71163Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030Xiaoyu Huang0Zhiqiang Zhang1Qiong Wu2Shaoyang Kang3Xinyue Yang4Fengmei Wang5School of Medicine Nankai University Tianjin ChinaGraduate School of Tianjin Medical University, Tianjin Medical University Tianjin ChinaSchool of Medicine Nankai University Tianjin ChinaSchool of Medicine Nankai University Tianjin ChinaGraduate School of Tianjin Medical University, Tianjin Medical University Tianjin ChinaDepartment of Gastroenterology and Hepatology, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer Tianjin First Central Hospital, Nankai University Tianjin ChinaABSTRACT Background Hepatoblastoma (HB) is the most common primary pediatric hepatocellular carcinoma, and the five‐year survival rate for HB is the lowest among childhood cancers, as 20% of cases are chemotherapy resistant or unresectable. Understanding the global burden of HB and future trends in HB burden is urgently needed for gastroenterology and hepatology specialists and pediatricians. This study aims to provide a comprehensive assessment of the global burden of hepatoblastoma, predict future trends over the next decade, and offer insights into its management. Methods Using data from the Global Burden of Disease 2021, trends in HB‐related mortality and disability‐adjusted life years (DALYs) were analyzed. Age‐standardized rates (ASR) and estimated annual percentage changes (EAPC) were employed to measure trends in these outcomes. Joinpoint regression identified trends, while Bayesian age‐period‐cohort (BAPC) modeling projected the future burden. Results Although the global number of HB‐related deaths decreased from 1990 to 2021, the number of deaths in 2021 in low socio‐demographic index (SDI) regions remained comparable to 1990 levels, with a notable upward trend in 27 countries, particularly in West Africa. Mortality and DALYs rates were highest in the early neonatal period, with the 2–4 years age group also showing the greatest burden. Projections indicate a global decline in HB burden from 2021 to 2030, but regions such as West Africa are likely to face persistent challenges. Conclusions In light of rapid population growth and escalating poverty in Africa, early screening and intervention for hepatoblastoma, particularly among children under five in low SDI regions, are critical to reducing the disease burden. These findings have significant implications for liver health policy, emphasizing the need for targeted interventions based on age and region to mitigate the impact of hepatoblastoma.https://doi.org/10.1002/cam4.71163Bayesian age‐period‐cohort modelingglobal burdenhepatoblastomapediatric populationprediction |
| spellingShingle | Xiaoyu Huang Zhiqiang Zhang Qiong Wu Shaoyang Kang Xinyue Yang Fengmei Wang Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030 Cancer Medicine Bayesian age‐period‐cohort modeling global burden hepatoblastoma pediatric population prediction |
| title | Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030 |
| title_full | Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030 |
| title_fullStr | Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030 |
| title_full_unstemmed | Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030 |
| title_short | Global Burden of Hepatoblastoma From 1990 to 2021 and Projection to 2030 |
| title_sort | global burden of hepatoblastoma from 1990 to 2021 and projection to 2030 |
| topic | Bayesian age‐period‐cohort modeling global burden hepatoblastoma pediatric population prediction |
| url | https://doi.org/10.1002/cam4.71163 |
| work_keys_str_mv | AT xiaoyuhuang globalburdenofhepatoblastomafrom1990to2021andprojectionto2030 AT zhiqiangzhang globalburdenofhepatoblastomafrom1990to2021andprojectionto2030 AT qiongwu globalburdenofhepatoblastomafrom1990to2021andprojectionto2030 AT shaoyangkang globalburdenofhepatoblastomafrom1990to2021andprojectionto2030 AT xinyueyang globalburdenofhepatoblastomafrom1990to2021andprojectionto2030 AT fengmeiwang globalburdenofhepatoblastomafrom1990to2021andprojectionto2030 |